Familial mediterranean fever: Risk factors, causes of death, and prognosis in the colchicine era

Medicine

Volumn 91, Issue 3, 2012, Pages 131-136

  Akar, Servet ^a   Yuksel, Feride ^a   Tunca, Mehmet ^a   Soysal, Ozgul ^a   Solmaz, Dilek ^a   Gerdan, Vedat ^a   Celik, Ali ^a   Sen, Gercek ^a   Onen, Fatos ^a   Akkoc, Nurullah ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE;

ADULT; AGING; AMYLOIDOSIS; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FAMILIAL MEDITERRANEAN FEVER; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RISK FACTOR; SOCIOECONOMICS; STANDARDIZED MORTALITY RATIO; STRUCTURED QUESTIONNAIRE; TELEPHONE; TURKEY (REPUBLIC); UNIVARIATE ANALYSIS; UNIVERSITY HOSPITAL;

AMYLOIDOSIS; CAUSE OF DEATH; COLCHICINE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; RISK FACTORS; SURVIVAL ANALYSIS; TURKEY;

EID: 84861097751     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0b013e3182561a45     Document Type: Article

References (42)

1. AkseyOnal V, Sag E, Ozen S, Bakkaloglu A, Cakar N, Besbas N, Gucer S. Decrease in the rate of secondary amyloidosis in Turkish children with FMF: Are we doing better? Eur J Pediatr. 2010;169:971y974.
2. Anonymous. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell. 1997;90:797-807.
3. Anonymous. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17:25-31.
4. BenyChetrit E, Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum. 2009;61:1447-1453.
5. BenyZvi I, Livneh A. Chronic inflammation in FMF: Markers, risk factors, outcomes and therapy. Nat Rev Rheumatol. 2011;7:105-112.
6. Blum A, Gafni J, Sohar E, Shibolet S, Heller H. Amyloidosis as the sole manifestation of familial Mediterranean fever (FMF). Further evidence of its genetic nature. Ann Intern Med. 1962;57:795-799.
7. Cattan D. Familial Mediterranean fever: Is low mortality from tuberculosis a specific advantage for MEFV mutations carriers? Mortality from tuberculosis among Muslims, Jewish, French, Italian and Maltese patients in Tunis (Tunisia) in the first half of the 20th century. Clin Exp Rheumatol. 2003;21(4 Suppl 30):S53-S54.
8. Cattan D. MEFV mutation carriers and diseases other than familial Mediterranean fever: Proved and nonyproved associations; putative biological advantage. Curr Drug Targets Inflamm Allergy. 2005;4:105-112.
9. Cazeneuve C, Ajrapetyan H, Papin S, RoudotyThoraval F, Genevieve D, Mndjoyan E, Papazian M, Sarkisian A, Babloyan A, Boissier B, Duquesnoy P, Kouyoumdjian JC, GirodonyBoulandet E, Grateau G, Sarkisian T, Amselem S. Identification of MEFVyindependent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet. 2000;67:1136-1143.
10. De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloidyA protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet. 1982;2:231-234.
11. Delibas A, Oner A, Balci B, Demircin G, Bulbul M, Bek K, Erdogan O, Baysun S, yilmaz E. Genetic risk factors of amyloidogenesis in familial Mediterranean fever. Am J Nephrol. 2005;25:434-440.
12. Dinc A, Pay S, Turan M, Simsek I. Prevalance of familial Mediterranean fever in young Turkish men Eabstract. Clin Exp Rheumatol. 2000;18:292.
13. Finkelstein y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, DubnovyRaz G, Pollak U, Koren G, Bentur y. Colchicine poisoning: The dark side of an ancient drug. Clin Toxicol (Phila). 2010;48:407-414.
14. Gafni J, Ravid M, Sohar E. The role of amyloidosis in familial Mediterranean fever. A population study. Isr J Med Sci. 1968;4:995-999.
15. GershoniyBaruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum. 2003;48:1149-1155.
16. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302.
17. Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, doubleyblind study. Ann Intern Med. 1974;81:792-794.
18. Hurwich BJ, Schwartz J, Golfarb S. Record survival of siblings with familial Mediterranean fever, phenotypes 1 and 2. Arch Intern Med. 1970;125:308-311.
19. Lachmann HJ, Sengul B, yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soyturk M, Akar S, Tunca M, Hawkins PN. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45:746-750.
20. Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol. 2000;14:477-498.
21. Livneh A, Langevitz P, Shinar y, Zaks N, Kastner DL, Pras M, Pras E. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid. 1999;6:1-6.
22. MedlejyHashim M, Delague V, Chouery E, Salem N, Rawashdeh M, Lefranc G, Loiselet J, Megarbane A. Amyloidosis in familial Mediterranean fever patients: Correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet. 2004;5:4.
23. Mor A, Shinar y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, Rabinovitz E, Livneh A. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum. 2005;35:57-64.
24. Onat A. Eriskinlerimizde Kalp Hastaliklari Prevalansi, yeni Koroner Olaylar ve Kalpten Olum Sikligi. In: Onat A, ed. TEKHARF Calismasi 2009. Istanbul; 2009:19-26.
25. Onat A. Toplumumuzda Kan Basinci ve Hipertansiyon. In: Onat A, ed. TEKHARF Calismasi 2009. Istanbul; 2009:74-88.
26. Onat A. Turk Eriskinlerinde Diyabet ve Prediyabet: Patogeneze Onemli Katki. In: Onat A, ed. TEKHARF Calismasi 2009. Istanbul; 2009:140-148.
27. Onen F. Familial Mediterranean fever. Rheumatol Int. 2006;26:489-496.
28. Onen F, Sumer H, Turkay S, Akyurek O, Tunca M, Ozdogan H. Increased frequency of familial Mediterranean fever in Central Anatolia, Turkey. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S31-S33.
29. Oner A, Erdogan O, Demircin G, Bulbul M, Memis L. Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatr Nephrol. 2003;18:521-526.
30. Ozkan E, Okur E, Ekmekci A. A new approach to the treatment of periodic fever. Med Bull Istanbul. 1972;5:44-49.
31. Pras M, Bronshpigel N, Zemer D, Gafni J. Variable incidence of amyloidosis in familial Mediterranean fever among different ethnic groups. Johns Hopkins Med J. 1982;150:22-26.
32. Saatci U, Ozen S, Ozdemir S, Bakkaloglu A, Besbas N, Topaloglu R, Arslan S. Familial Mediterranean fever in children: Report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr. 1997;156:619-623.
33. Schwabe AD, Peters RS. Familial Mediterranean fever in Armenians. Analysis of 100 cases. Medicine (Baltimore). 1974;53:453-462.
34. Sevoyan MK, Sarkisian TF, Beglaryan AA, Shahsuvaryan GR, Armenian HK. Prevention of amyloidosis in familial Mediterranean fever with colchicine: A caseycontrol study in Armenia. Med Princ Pract. 2009;18:441-446.
35. Shohat M, Magal N, Shohat T, Chen X, Dagan T, Mimouni A, Danon y, Lotan R, Ogur G, Sirin A, Schlezinger M, Halpern GJ, Schwabe A, Kastner D, Rotter JI, FischelyGhodsian N. Phenotypeygenotype correlation in familial Mediterranean fever: Evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet. 1999;7:287-292.
36. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43:227-253.
37. Tekin M, yalcinkaya F, Cakar N, Akar N, Misirlioglu M, Tastan H, Tumer N. MEFV mutations in multiplex families with familial Mediterranean fever: Is a particular genotype necessary for amyloidosis? Clin Genet. 2000;57:430-434.
38. Touitou I, Sarkisian T, MedlejyHashim M, Tunca M, Livneh A, Cattan D, yalcinkaya F, Ozen S, Majeed H, Ozdogan H, Kastner D, Booth D, BenyChetrit E, Pugnere D, Michelon C, Seguret F, GershoniyBaruch R. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum. 2007;56:1706-1712.
39. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, yalcinkaya F, Tutar E, Ozen S, Topaloglu R, yilmaz E, Arici M, Bakkaloglu A, Besbas N, Akpolat T, Dinc A, Erken E. Familial Mediterranean fever (FMF) in Turkey: Results of a nationwide multicenter study. Medicine (Baltimore). 2005;84:1-11.
40. Tunca M, Kirkali G, Soyturk M, Akar S, Pepys MB, Hawkins PN. Acute phase response and evolution of familial Mediterranean fever. Lancet. 1999;353:1415.
41. Zemer D, Livneh A, Langevitz P. Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann Intern Med. 1992;116:426.
42. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314:1001-1005.